|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
JPS60192263A
(ja)
|
1984-03-13 |
1985-09-30 |
Teijin Ltd |
免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
CA1276103C
(en)
*
|
1984-10-02 |
1990-11-13 |
Fumiaki Taguchi |
Substance-conjugated complement component c1q
|
|
JPS61271455A
(ja)
*
|
1985-05-28 |
1986-12-01 |
Olympus Optical Co Ltd |
免疫学的分析方法
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US4866132A
(en)
|
1986-04-17 |
1989-09-12 |
The Research Foundation Of State University Of New York |
Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
DE3853515T3
(de)
|
1987-05-21 |
2005-08-25 |
Micromet Ag |
Multifunktionelle proteine mit vorbestimmter zielsetzung.
|
|
US5256334A
(en)
|
1988-09-08 |
1993-10-26 |
The Research Foundation Of The State University Of New York |
Homogeneous radiopaque polymer-organobismuth composites
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5595732A
(en)
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
DE69233013T2
(de)
|
1991-08-20 |
2004-03-04 |
The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer |
Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
|
|
JP3540315B2
(ja)
|
1991-09-23 |
2004-07-07 |
メディカル リサーチ カウンシル |
キメラ抗体の製造−組合せアプローチ
|
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
|
AU3178993A
(en)
|
1991-11-25 |
1993-06-28 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
CA2592997A1
(en)
|
1992-12-03 |
1994-06-09 |
Genzyme Corporation |
Pseudo-adenovirus vectors
|
|
US5346981A
(en)
|
1993-01-13 |
1994-09-13 |
Miles Inc. |
Radiopaque polyurethanes
|
|
DE614989T1
(de)
|
1993-02-17 |
1995-09-28 |
Morphosys Proteinoptimierung |
Verfahren für in vivo Selektion von Ligandenbindende Proteine.
|
|
JP3532566B2
(ja)
|
1993-06-24 |
2004-05-31 |
エル． グラハム，フランク |
遺伝子治療のためのアデノウイルスベクター
|
|
DK0716611T3
(da)
|
1993-09-01 |
2002-05-21 |
Sanquin Bloedvoorziening |
Fremgangsmåde til at reducere myocardielæsion under akut myocardieinfarkt
|
|
JP3875990B2
(ja)
|
1993-10-25 |
2007-01-31 |
カンジ，インコーポレイテッド |
組換えアデノウイルスベクターおよび使用方法
|
|
US5643575A
(en)
|
1993-10-27 |
1997-07-01 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
|
US5625048A
(en)
|
1994-11-10 |
1997-04-29 |
The Regents Of The University Of California |
Modified green fluorescent proteins
|
|
KR100445103B1
(ko)
|
1994-12-09 |
2004-12-04 |
임페리얼 컬리지 이노베이션스 리미티드 |
유전자의동정
|
|
US5939045A
(en)
|
1994-12-22 |
1999-08-17 |
Nissan Chemical Industries, Ltd. |
Organic bismuth derivatives for X-ray imaging
|
|
US5958713A
(en)
|
1995-01-31 |
1999-09-28 |
Novo Nordisk A/S |
Method of detecting biologically active substances by using green fluorescent protein
|
|
US5670477A
(en)
|
1995-04-20 |
1997-09-23 |
Joseph F. Poduslo |
Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
|
|
US5968738A
(en)
|
1995-12-06 |
1999-10-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
|
|
US5874304A
(en)
|
1996-01-18 |
1999-02-23 |
University Of Florida Research Foundation, Inc. |
Humanized green fluorescent protein genes and methods
|
|
US6020192A
(en)
|
1996-01-18 |
2000-02-01 |
University Of Florida |
Humanized green fluorescent protein genes and methods
|
|
US5968511A
(en)
*
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
|
ATE208629T1
(de)
|
1996-08-27 |
2001-11-15 |
Chiron Corp |
Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
|
|
US5976796A
(en)
|
1996-10-04 |
1999-11-02 |
Loma Linda University |
Construction and expression of renilla luciferase and green fluorescent protein fusion genes
|
|
TW371617B
(en)
|
1996-10-09 |
1999-10-11 |
Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau |
Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV
|
|
US6969601B2
(en)
|
1997-04-03 |
2005-11-29 |
Jensenius Jens Chr |
MASP-2, a complement-fixing enzyme, and uses for it
|
|
US6080849A
(en)
|
1997-09-10 |
2000-06-27 |
Vion Pharmaceuticals, Inc. |
Genetically modified tumor-targeted bacteria with reduced virulence
|
|
KR20010015856A
(ko)
|
1997-12-12 |
2001-02-26 |
마크로메드 인코퍼레이션 |
단백질 변성용으로 헤테로 작용기를 가진 별 모양의폴리(에틸렌글리콜)
|
|
DE69939813D1
(de)
*
|
1998-02-20 |
2008-12-11 |
Tanox Inc |
Inhibitoren der komplement-aktivierung
|
|
US5985577A
(en)
|
1998-10-14 |
1999-11-16 |
The Trustees Of Columbia University In The City Of New York |
Protein conjugates containing multimers of green fluorescent protein
|
|
WO2000047194A2
(en)
|
1999-02-09 |
2000-08-17 |
3-Dimensional Pharmaceuticals, Inc. |
METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
|
|
AU4369000A
(en)
|
1999-04-26 |
2000-11-10 |
Duke University |
Inhibition of complement action
|
|
AU6929100A
(en)
|
1999-08-23 |
2001-03-19 |
Biocrystal Limited |
Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
|
|
EP1250594A4
(en)
|
2000-01-19 |
2003-05-07 |
Biotransplant Inc |
PORC UNABLE TO TRANSMIT PORCINE ENDOGENEOUS RETROVIRUS, AND USES THEREOF
|
|
ES2299473T3
(es)
|
2000-01-31 |
2008-06-01 |
Pharming Intellectual Property B.V. |
Inhibidor de c1 humano producido en la leche de mamiferos transgenicos.
|
|
ATE435873T1
(de)
|
2000-03-23 |
2009-07-15 |
Genentech Inc |
Anti-c2/c2a inhibitoren zur komplement aktivierung
|
|
CA2413830A1
(en)
|
2000-06-21 |
2001-12-27 |
Zymogenetics, Inc. |
Peptide and polypeptide inhibitors of complement c1s
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
GB0105924D0
(en)
|
2001-03-09 |
2001-04-25 |
Microscience Ltd |
Promoter
|
|
GB0117326D0
(en)
|
2001-07-16 |
2001-09-05 |
Univ Aberdeen |
Napthoquinone-type inhibitors of protein aggregation
|
|
US20030049260A1
(en)
|
2001-07-26 |
2003-03-13 |
Leonard Bell |
Method of improving cognitive function
|
|
KR100754596B1
(ko)
|
2001-09-21 |
2007-09-05 |
미쯔비시 웰 파마 가부시키가이샤 |
3-치환-4-피리미돈 유도체
|
|
CA2470195A1
(en)
|
2002-01-11 |
2003-08-07 |
Gtc Biotherapeutics, Inc. |
Method and system for fusion and activation following nuclear transfer in reconstructed embryos
|
|
US20080206242A1
(en)
|
2002-03-01 |
2008-08-28 |
Xencor, Inc. |
Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
|
|
SE0202880D0
(sv)
|
2002-07-26 |
2002-09-30 |
Wieslab Ab |
Complement system deficiency assay
|
|
US7666627B2
(en)
|
2002-08-08 |
2010-02-23 |
Targetex Kft. |
Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
|
|
EP1545611B1
(en)
|
2002-09-06 |
2016-11-09 |
Alexion Pharmaceuticals, Inc. |
Method of treatment of asthma using antibodies to complement component c5
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
US7361339B2
(en)
|
2003-01-09 |
2008-04-22 |
Alexion Pharmaceuticals, Inc. |
Methods for reducing morality associated with acute myocardial infarction
|
|
JP4768620B2
(ja)
|
2003-05-15 |
2011-09-07 |
ジェネンテック， インコーポレイテッド |
敗血症の予防及び治療のための方法及び組成物
|
|
WO2005014849A2
(en)
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
|
US7482376B2
(en)
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
|
US8501705B2
(en)
|
2003-09-11 |
2013-08-06 |
The Board Of Regents Of The University Of Texas System |
Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
|
|
US7923010B2
(en)
|
2003-09-11 |
2011-04-12 |
The Board Of Regents Of The University Of Texas System |
Methods and materials for treating autoimmune diseases and conditions
|
|
EP2311945A1
(en)
*
|
2003-10-14 |
2011-04-20 |
Chugai Seiyaku Kabushiki Kaisha |
Bispecific antibodies substituting for functional proteins
|
|
AU2004297616B2
(en)
|
2003-12-04 |
2008-12-18 |
Xencor, Inc. |
Methods of generating variant proteins with increased host string content and compositions thereof
|
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
BR122019012028B1
(pt)
|
2004-04-13 |
2023-09-26 |
F. Hoffmann-La Roche Ag |
Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição
|
|
WO2005123776A1
(en)
|
2004-06-10 |
2005-12-29 |
Omeros Corporation |
Methods for treating conditions associated with lectin-dependent complement activation
|
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US8840893B2
(en)
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
PL2465534T3
(pl)
|
2004-06-10 |
2017-08-31 |
Omeros Corporation |
Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2
|
|
KR20070034512A
(ko)
|
2004-06-18 |
2007-03-28 |
암브룩스, 인코포레이티드 |
신규 항원-결합 폴리펩티드 및 이의 용도
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
BRPI0517837A
(pt)
|
2004-11-12 |
2008-10-21 |
Xencor Inc |
variantes fc com ligação alterada a fcrn
|
|
US8420783B2
(en)
|
2004-12-08 |
2013-04-16 |
Immunomedics, Inc. |
Method and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases
|
|
US20090016959A1
(en)
|
2005-02-18 |
2009-01-15 |
Richard Beliveau |
Delivery of antibodies to the central nervous system
|
|
AU2006227778A1
(en)
|
2005-03-16 |
2006-09-28 |
Janssen Pharmaceutica N.V. |
Novel thiophene sulfoximines for treating complement-mediated diseases and conditions
|
|
EP1896503B1
(en)
|
2005-05-31 |
2014-10-29 |
Board of Regents, The University of Texas System |
IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF
|
|
CA2654440C
(en)
|
2005-06-06 |
2013-09-03 |
Girish J. Kotwal |
Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
|
|
WO2007022416A2
(en)
|
2005-08-18 |
2007-02-22 |
Ramot At Tel Aviv University Ltd. |
Single chain antibodies against beta-amyloid peptide
|
|
US8741260B2
(en)
|
2005-10-07 |
2014-06-03 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of GDNF to the CNS
|
|
WO2007047995A2
(en)
|
2005-10-21 |
2007-04-26 |
Catalyst Biosciences, Inc. |
Modified proteases that inhibit complement activation
|
|
US8148330B2
(en)
|
2005-12-09 |
2012-04-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of synaptic maintenance
|
|
US9480658B2
(en)
|
2005-12-09 |
2016-11-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of synaptic maintenance
|
|
HRP20110622T1
(hr)
|
2005-12-21 |
2011-09-30 |
Pharming Intellectual Property B.V. |
Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede
|
|
FR2897868B1
(fr)
|
2006-02-24 |
2012-08-31 |
Lab Francais Du Fractionnement |
Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
|
|
HUE026496T2
(en)
|
2006-03-08 |
2016-06-28 |
Archemix Llc |
Complement-binding aptamers and anti-C5 agents for treating eye diseases
|
|
MY159375A
(en)
|
2006-03-21 |
2016-12-30 |
Genentech Inc |
Combinatorial therapy
|
|
EP2380907B1
(en)
|
2006-09-05 |
2016-11-30 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for the treatment of antibody mediated neuropathies
|
|
EP3028716B1
(en)
|
2006-10-10 |
2020-09-16 |
Regenesance B.V. |
Complement inhibition for improved nerve regeneration
|
|
US7858752B2
(en)
*
|
2006-12-05 |
2010-12-28 |
Abbott Laboratories |
Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
|
|
CN101679219B
(zh)
*
|
2006-12-19 |
2014-08-13 |
港大科桥有限公司 |
合成离子通道
|
|
EP2148691B1
(en)
|
2007-02-05 |
2015-05-20 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
|
|
US8192742B2
(en)
|
2007-03-23 |
2012-06-05 |
NovelMed Therapeutics |
Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
|
|
MY150531A
(en)
|
2007-07-16 |
2014-01-30 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
WO2009035786A1
(en)
|
2007-08-03 |
2009-03-19 |
Genentech, Inc. |
Humanized anti-fgf19 antagonists and methods using same
|
|
ES2742268T3
(es)
|
2007-12-26 |
2020-02-13 |
Xencor Inc |
Variantes de Fc con unión alterada a FcRn
|
|
US20110190221A1
(en)
|
2008-03-28 |
2011-08-04 |
Apellis Ag |
Modulation and repletion/enhancement of the complement system for treatment of trauma
|
|
EP2283355A2
(en)
|
2008-04-25 |
2011-02-16 |
Zymogenetics, Inc. |
Levels of bcma protein expression on b cells and use in diagnostic methods
|
|
ES2675730T3
(es)
|
2008-06-04 |
2018-07-12 |
Macrogenics, Inc. |
Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
|
|
US20090324585A1
(en)
|
2008-06-12 |
2009-12-31 |
The Trustees of the Leland Standford Junior University |
Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
|
|
WO2010015608A1
(en)
*
|
2008-08-05 |
2010-02-11 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5
|
|
US20110311550A1
(en)
*
|
2008-10-24 |
2011-12-22 |
The Scripps Research Institute |
Agents for hcv treatment
|
|
RS64039B1
(sr)
|
2008-11-10 |
2023-04-28 |
Alexion Pharma Inc |
Metode i kompozicije za lečenje poremećaja povezanih sa komplementom
|
|
CN105866426B
(zh)
|
2008-12-01 |
2018-11-23 |
小利兰·斯坦福大学托管委员会 |
用于检测补体结合性抗体的方法和组合物
|
|
EP3153524B1
(en)
|
2008-12-03 |
2025-04-23 |
Genmab A/S |
Antibody variants having modifications in the constant region
|
|
CN103665170A
(zh)
|
2008-12-05 |
2014-03-26 |
安吉奥开米公司 |
肽治疗剂轭合物及其应用
|
|
US8401799B2
(en)
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
|
US20100291106A1
(en)
*
|
2009-05-06 |
2010-11-18 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c3b
|
|
NZ597259A
(en)
*
|
2009-06-23 |
2014-04-30 |
Alexion Pharma Inc |
Bispecific antibodies that bind to complement proteins
|
|
TW201117824A
(en)
*
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
|
CN106390117A
(zh)
|
2009-10-16 |
2017-02-15 |
奥默罗斯公司 |
通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法
|
|
JP5851391B2
(ja)
*
|
2010-02-16 |
2016-02-03 |
国立大学法人京都工芸繊維大学 |
抗体固定化担体、抗体固定化担体の製造方法および当該抗体固定化担体の利用
|
|
WO2011109338A1
(en)
|
2010-03-01 |
2011-09-09 |
Alexion Pharmaceuticals Inc. |
Methods and compositions for treating degos' disease
|
|
KR101800913B1
(ko)
|
2010-04-30 |
2017-12-20 |
알렉시온 파마슈티칼스, 인코포레이티드 |
항-c5a 항체들과 이 항체들을 이용하는 방법
|
|
CA2799746C
(en)
*
|
2010-05-17 |
2020-11-24 |
Sai Reddy |
Rapid isolation of monoclonal antibodies from animals
|
|
WO2011163394A2
(en)
|
2010-06-22 |
2011-12-29 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of neuropathic pain
|
|
EP2585110A4
(en)
|
2010-06-22 |
2014-01-22 |
Univ Colorado Regents |
ANTIBODIES AGAINST THE C3D FRAGMENT OF THE COMPLEMENT COMPONENT 3
|
|
TWI560199B
(en)
|
2010-08-31 |
2016-12-01 |
Sanofi Sa |
Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
|
|
TW201241008A
(en)
|
2010-10-01 |
2012-10-16 |
Alexion Pharma Inc |
Polypeptides that bind to human complement component C5
|
|
US8865164B2
(en)
|
2010-11-02 |
2014-10-21 |
Kypha, Inc. |
Detecting complement activation
|
|
EP3461847B1
(en)
|
2010-12-06 |
2020-09-23 |
Seattle Genetics, Inc. |
Humanized antibodies to liv-1 and use of same to treat cancer
|
|
CN103429261A
(zh)
|
2010-12-22 |
2013-12-04 |
塞法隆澳大利亚股份有限公司 |
半寿期改进的修饰抗体
|
|
KR20220044616A
(ko)
*
|
2011-04-08 |
2022-04-08 |
유니버시티 오브 레스터 |
Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
|
|
EP2704743B1
(en)
|
2011-05-04 |
2020-03-11 |
Omeros Corporation |
Compositions for inhibiting masp-2 dependent complement acitivation
|
|
US9289467B2
(en)
|
2011-08-10 |
2016-03-22 |
Case Western Reserve University |
Compositions and methods for treating bone conditions
|
|
EP2793935B1
(en)
|
2011-12-22 |
2016-05-25 |
CSL Behring GmbH |
Use of c1-inhibitor for the treatment of secondary edema of the central nervous system
|
|
JP6081699B2
(ja)
|
2011-12-28 |
2017-02-15 |
雅史 溝上 |
Ｉｌ−２８ｂの分析方法
|
|
KR102041412B1
(ko)
|
2011-12-30 |
2019-11-11 |
한미사이언스 주식회사 |
면역글로불린 Ｆｃ 단편 유도체
|
|
EP2912065A4
(en)
|
2012-10-25 |
2016-10-19 |
True North Therapeutics Inc |
ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
|
|
RS63212B1
(sr)
*
|
2012-11-02 |
2022-06-30 |
Bioverativ Usa Inc |
Antikomplementna c1s antitela i njihove primene
|
|
AU2014213147B2
(en)
|
2013-01-31 |
2019-01-17 |
lmmunAbs Inc. |
C5 antibody and method for preventing and treating complement-related diseases
|
|
US20140294812A1
(en)
|
2013-03-15 |
2014-10-02 |
Xencor, Inc. |
Fc variants that improve fcrn binding and/or increase antibody half-life
|
|
EP2996722A4
(en)
*
|
2013-05-15 |
2017-01-11 |
Annexon, Inc. |
Methods of treatment for guillain-barre syndrome
|
|
CA2912568A1
(en)
|
2013-05-30 |
2014-12-04 |
Plexxikon Inc. |
Compounds for kinase modulation, and indications therefor
|
|
KR102321320B1
(ko)
|
2013-07-09 |
2021-11-03 |
애넥슨, 인코포레이티드 |
항-보체 인자 ｃ１ｑ 항체 및 이의 용도
|
|
WO2015084999A1
(en)
|
2013-12-06 |
2015-06-11 |
True North Therapeutics, Inc. |
Complement component biomarker assays
|
|
AU2015332151A1
(en)
|
2014-10-18 |
2017-04-27 |
Pfizer Inc. |
Anti-IL-7R antibody compositions
|
|
BR112017021289A2
(en)
|
2015-04-06 |
2018-06-26 |
Bioverativ Usa Inc. |
humanized anti-c1s antibodies and methods of use
|
|
EP3313417A4
(en)
|
2015-06-26 |
2019-06-12 |
Bioverativ USA Inc. |
METHOD FOR TREATING AUTOIMMUNE AND ALLOIMMUNE DISEASES
|
|
EP3525583B8
(en)
|
2016-10-12 |
2025-09-10 |
Bioverativ USA Inc. |
Anti-c1s antibodies and methods of use thereof
|
|
US20210115116A1
(en)
|
2017-03-14 |
2021-04-22 |
Bioverativ Usa Inc. |
Methods for treating complement-mediated diseases and disorders
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
MX2020010528A
(es)
|
2018-04-13 |
2020-11-06 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-componente de complemento y metodos de uso.
|
|
MY209127A
(en)
|
2018-10-18 |
2025-06-23 |
Merck Sharp & Dohme Llc |
Formulations of anti-rsv antibodies and methods of use thereof
|
|
MX2023001492A
(es)
|
2020-08-06 |
2023-03-08 |
Bioverativ Usa Inc |
Citocinas inflamatorias y fatiga en sujetos con una enfermedad mediada por el complemento.
|